Standard Chartered Bank has tied up with Pinpoint India to accelerate reward points for customers when transacting at multiple Bonus Points Partners across India
Standard Chartered Bank has launched 'Bonus Points' to enhance the reward earning potential for its Premium Credit Cardholders. The bank has tied up with Pinpoint India Pvt Ltd to accelerate reward points for customers when transacting at multiple Bonus Points Partners across India.
In addition to reward points, Standard Chartered Credit card customers will automatically earn Bonus Points, every time they use their eligible credit cards to shop at participating merchants. These merchants include Croma, Vodafone, Wills Lifestyle, The Leela Palaces and Hotels, Marriott Hotels, Cox & Kings, Jimmy Choo, Bottega Veneta, VLCC and many more.
Cardholders can also earn Bonus Points across a large number of local merchants such as optometrists, beauty salons, boutiques, florists, jewellers, book stores and restaurants. Bonus Points are earned every day of the year, even during sales.
The Advertising Standards Council acts on complaints against 34 advertisers for incorrect claims or unethical depiction. Some companies withdraw their advertisements altogether
In order to highlight the 'body balance' advantage, TVS Wego's television commercial had two women pulling off dance-inspired stunts on the back seat of the scooty. It probably did attract a lot of attention, and who knows may have helped push sales for TVS too, but the Advertising Standards Council of India (ASCI) has pulled up the advertiser for displaying such stunts in regular traffic. (TVS Wego advertisement)
The TVS Wego commercial is one of several ads that the Consumer Complaints Council (CCC) of ASCI received complaints about during November 2010 to February 2011, and has ordered the advertisers to either modify their campaigns or withdraw them altogether.
Among the 34 names are such prominent companies like Dabur, Hindustan Unilever (HUL), ITC, L'Oreal, Procter & Gamble (P&G), Reebok India and Hyundai Motors; they range from FMCGs to autos, personal accessories to alcohol, and education to media.
Complaints against TV ads by HUL, P&G, L'Oreal, Dabur, Dish TV, Kent RO Systems, Shree Maruti Herbal questioned the comparisons they made or the comparative benefits they claimed. ITC's commercial for its Vivel personal care products has been discontinued for the unethical depiction of women with dark skin.
Explaining the process of scrutiny of complaints, Alan J Collaco, secretary general, ASCI, told Moneylife, "While screening the complaints we make a scientific comparison of the claims by these brands and then further action is taken. If we find their claims to be untrue, then we ask them to modify the commercial. For example, we ask them to drop their claim of being number one. The Vivel ad, which depicted dark women as having an unfair advantage, is incorrect and unethical. So the ad was pulled out."
The advertisements for T.I.M.E. Institute's MBA-CET 2010 and Noesis Education have been altered. Noesis Education's claim of a success ratio of one out of eight students sent to IIM was not substantiated.
As in the case of TVS Wego which screened dangerous acts, Ceat modified its campaign, whereas Hyundai withdrew its commercial altogether.
Pernod Ricard's Royal Stag advertisement was discontinued on a complaint that it was using surrogate advertising for an alcohol product through the medium of cricket matches. Similarly, Sab Miller India (Hayward & Hayward 5000) and United Spirits (McDowell's) were withdrawn for violating the Cable TV Network Rules and ASCI's code on surrogate advertising. In India, advertising alcohol brands even in a surrogate form is banned.
The Dainik Bhaskar and Pudhari advertisements have also been withdrawn on complaints about the claims they made. "Dainik Bhaskar claimed to be number one in Ranchi, which is not true. Others also made similar claims of being number one in their own regions. So their ads were withdrawn," Mr Collaco said.
ASCI also upheld complaints against television commercials by New Look Skincare, Lavanya Ayurvedic Cancer Hospital, Reebok India, Indiatimes Shopping and Lokmat newspaper for making unsubstantiated or misleading claims. American Tourister, Naaptol, Career Launcher and IMS Learning Resources were other advertisers against whom ASCI acted on complaints.
ASCI has been receiving a steady stream of complaints. "There is definitely a lot of awareness among people. This has helped us to take action against misleading and unethical ads," Mr Collaco said.
Lupin has signed a licensing agreement with NeuClone Pty Ltd for cell line technology to develop cancer treatment medicines
Drug maker Lupin has signed a licensing agreement with Sydney based private specialty life science company NeuClone Pty Ltd for cell line technology to develop cancer treatment medicines.
“Under the terms of the agreement, NeuClone will provide an exclusive proprietary mammalian CHO cell line which will express a specific recombinant protein of interest in oncology to its partner,” Lupin said in a statement.
The agreement will also entail the Lupin Biological Research Programme scientific research staff to work with NeuClone teams at their facility as part of the overall technology transfer arrangements specified within the agreement, it added.
Cyrus Karkaria, president and head, Lupin Biological Research Programme, “The multi-billion dollar opportunity, with blockbuster biologics going off patent in the next 5-8 years, is something that Lupin is pursuing aggressively”.
“This exclusive licensing arrangement with NeuClone is a part of that strategy and would enable us to capitalise on cutting edge technology to address the biologicals market.”
He further said that such agreements coupled with the company’s own products pipeline will go a long way in helping it address the impending opportunity and develop a substantial differentiated biological pipeline.
The company currently has 6-8 products (proteins) in the pipeline and is looking to launch its first biological in the Indian market by the middle of 2011.
NeuClone CEO, Mr Noelle Sunstrom said: “This is an exciting time for NeuClone and our stakeholders as our investment in mammalian CHO cell lines is commercialised. In particular, we are enthusiastic about further developing the relationship with Lupin, an important global generic manufacturer.”
According to industry estimates, the market for biosimilars globally is pegged at over $100 billion, whereas the Indian market for biosimilars—including insulin, hormones, vaccines and plasma proteins—is valued at around Rs2,500 crore.
On Wednesday, Lupin ended 0.85% down at Rs465.85 on the Bombay Stock Exchange, while the benchmark Sensex gained 0.57% to 18,608.81.